Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

9/18/2007 Email - XYNTHA

From: Kearns, Daniel

Sent: Tuesday, September 18, 2007 11:29 AM

To: Lee, Timothy; Renshaw, Carolyn

Cc: Trout, Deborah; Cottrell, Pauline; Stephenson, Franklin

Subject: Memo of Telecon Wyeth 125264-0


DATE: Tuesday, September 18, 2007 at about 11:05 am
FROM: Daniel Kearns, HFM-675
TO: D. Gates, Wyeth representative
SUBJECT: Bioburden results pre or post filtration; shared equipment at ------------------------- cell testing

I (DK) called and spoke to D. Gates, the Wyeth representative for CMC issues for STN 125264. I said that there were 3 points for which some clarification were needed:

  1. In section 3.2.S.2.5 (see table 3-3 for example) all the bioburden results are 0 (zero) - we wanted to determine if that represents sampling prior to filtration
  2. With regard to ---------------------------------, and what appears to be shared equipment with highly potent compounds, clarification as to what compounds and what equipment is shared, and the cleaning specifications (e.g., 1/1000th of a therapeutic dose)
  3. Are each lot of ----------------- cells tested for ---------- (Mr. Gates responded that they are, and each ----------------- lot is tested in full (----------------------------- - I asked for the reference and he will supply).

Mr. Gates said he would get the information to me as soon as possible. The conversation concluded.

Prepared by D.Kearns on Tuesday, September 18, 2007 at about 11:30 am

Page Last Updated: 06/13/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English